Arcturus Therapeutics Holdings Inc. (ARCT) Discusses Phase II Data for OTC Deficiency and Advances in mRNA Liver Therapeutics Platform Transcript

Arcturus Therapeutics Holdings Inc. ( ARCT ) Discusses Phase II Data for OTC Deficiency and Advances in mRNA Liver Therapeutics Platform September 23, 2026 4:30 PM EDT Company Participants Neda Safarzadeh - Vice President and Head of IR/PR & Marketing Joseph Payne - Founder, President, CEO & Director Alan Cohen - Chief Medical Officer Padmanabh Chivukula - Founder, Chief Scientific Officer, COO & Secretary Conference Call Participants Marshall Summar Myles Minter - William Blair & Company L.L.C., Research Division Pete Stavropoulos Lili Nsongo - Leerink Partners LLC, Research Division Yanan Zhu - Wells Fargo Securities, LLC, Research Division Boran Wang - Guggenheim Securities, LLC, Research Division Yigal Nochomovitz - Citigroup Inc. Exchange Research Adam Walsh - ROTH Capital Partners, LLC, Research Division Whitney Ijem - Canaccord Genuity Corp., Research Division Mayank Mamtani - B. Riley Securities, Inc., Research Division Yale Jen - Laidlaw & Company ( UK ) Ltd., Research Division Presentation Operator Hello and welcome, everyone, joining today's Arcturus Therapeutics' presentation. [Operator Instructions] Please note, this call is being recorded, and we are standing by if you should need any assistance. It is now my pleasure to turn the meeting over to Neda Safarzadeh, Vice President, Head of Investor Relations, Public Relations and Marketing. Please go ahead. Neda Safarzadeh Vice President and Head of IR/PR & Marketing Thank you, operator. Good afternoon, and welcome to Arcturus Therapeutics presentation. Today's call will be led by Joe Payne, our President and CEO; Dr. Alan Cohen, our Chief Medical Officer; Dr. Marshall Summar, a recognized expert in rare diseases and OTC deficiency and Dr. Pad Chivukula, our Chief Scientific Officer. Before we begin, please note that today's call may contain forward-looking statements. Such statements are based on current expectations and assumptions, and actual results may differ. Please refer to our filings made with the SEC, including the risk factors contained therein for more information. We undertake no obligation to update any forward-looking statement. And